Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

1(20%)

Results Posted

0%(0 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_2

40%

Ph phase_1

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

3(60.0%)

Phase 2Efficacy & side effects

2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Terminated(1)

Detailed Status

Completed3

Recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (60.0%)

Phase 22 (40.0%)

Trials by Status

recruiting120%

terminated120%

completed360%

Recent Activity

1 active trials

Showing 5 of 5

recruitingphase_2

A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects

NCT05995444

completedphase_1

A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function

NCT05283746

Clinical Trials (5)

Showing 5 of 5 trials

NCT07301320Phase 2

Epetraborole in Patients With Mycobacterium Abscessus Lung Disease

Recruiting

NCT05327803Phase 2

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

Terminated

NCT04892641Phase 1

Phase 1 Study of Epetraborole Tablets

Completed

NCT05995444Phase 1

A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects

Completed

NCT05283746Phase 1

A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5